FIRST TRACKS BIOTHERAPEUTICS, INC. Net Fee Amt
FIRST TRACKS BIOTHERAPEUTICS, INC. (TRAX) had Net Fee Amt of $30.41 thousand as of 2026-05-07, per its S-1 filed 2026-05-08.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-05-08
- 2026-05-07: Net Fee Amt $30.41K.
- 2026-04-17: Net Fee Amt $44.49K.
| Period end | Net Fee Amt |
|---|---|
| 2026-05-07 | $30.41K S-1 · filed 2026-05-08 |
| 2026-04-17 | $44.49K S-8 · filed 2026-04-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B |